Market - iData Insights - ReDiscovering Data | Research Reports, News, Events, Research on Demand

Sectors


Price








Published







Research Reports Titles

  • Human Immunodeficiency Virus (HIV) - China Drug Forecast and Market Analysis to 2023

    Human Immunodeficiency Virus (HIV) - China Drug Forecast and Market Analysis to 2023 Summary Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKline s (GSK s) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART). This rapid progress has been headlined by the emergence of once-daily, single-tablet regimens (STRs) such as Gilead Science's Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]), which offer patients an unparalleled level of convenience. The HIV therapeutics market in China was valued at approximately $144m in 2013. In contrast to the 7MM, where branded therapies dominate the treatment landscape, generics are beginning to seize market share from their pricier alternatives, and they will continue to gain traction during the forecast period, as China is expected to adopt a more aggressive policy towards identifying and treating people living with HIV. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Overview of Human Immunodeficiency Virus (HIV) including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in the China including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in the China from 2013-2023. - Analysis of the impact of key events as well the drivers and restraints affecting the China Human Immunodeficiency Virus (HIV) market. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Human Immunodeficiency Virus (HIV). - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2013-2023 in the China.

    • Release Date: September 09, 2015
    • Price: USD 4995
    • Format: PDF

  • Human Immunodeficiency Virus (HIV) - Current and Future Players

    Human Immunodeficiency Virus (HIV) - Current and Future Players Summary GlobalData has released its pharma report,  Human Immunodeficiency Virus (HIV) - Current and Future Players . The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Human Immunodeficiency Virus (HIV) Market. The report identifies and analyses the key companies shaping and driving the global Human Immunodeficiency Virus (HIV) market. The report provides insight into the competitive Human Immunodeficiency Virus (HIV) landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData s team of industry experts. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Investigation of current and future market competition for Human Immunodeficiency Virus (HIV) - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Human Immunodeficiency Virus (HIV) sector through market impact analysis, future market scenario and company analysis Reasons to buy - Gain a high level view of the trends shaping and driving Human Immunodeficiency Virus (HIV) market - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market - What s the next big thing in the global Human Immunodeficiency Virus (HIV) market landscape? Identify, understand and capitalize

    • Release Date: September 09, 2015
    • Price: USD 2995
    • Format: PDF

  • Multiple Myeloma - Market Insights, Epidemiology and Market Forecast-2023

    Note*: This report requires 7-10 business days to complete. DelveInsight s Multiple Myeloma - Market Insights, Epidemiology and Market Forecast-2023 Reports provides an overview of the disease and global market trends of the Multiple Myeloma for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Multiple Myeloma forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Multiple Myeloma till 2023. Key Coverage and Benefits " The report will help in developing business strategies by understanding the trends shaping and driving the global Multiple Myeloma market. " Identifying patient populations in the global  Multiple Myeloma market to improve product design, pricing, and launch plans. " Organize sales and marketing efforts by identifying the best opportunities for Multiple Myeloma therapeutics in each of the markets covered. " To understand the future market competition in the global Multiple Myeloma therapeutics market and Insightful review of the key market drivers and barriers. Scope " Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options. " Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018. " The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2013-2023. " It also provides Multiple Myeloma for United States, EU5 and Japan from 2013 and forecasted Market to 2023.

    • Release Date: December 31, 1899
    • Price: USD 4950
    • Format: pdf


Create Account



Log In Your Account